

NUCLEAR REGULATORY COMMISSION

ORIGINAL

Title: Advisory Committee on Nuclear Waste
152nd Meeting

Docket Number: (not applicable)

PROCESS USING ADAMS
TEMPLATE: ACRS/ACNW-005

Location: Rockville, Maryland

Date: Wednesday, July 21, 2004

Work Order No.: NRC-1596

Pages 1-69

NEAL R. GROSS AND CO., INC.
Court Reporters and Transcribers
1323 Rhode Island Avenue, N.W.
Washington, D.C. 20005
(202) 234-4433

**ADVISORY OFFICE COPY - RETAIN FOR
THE LIFE OF THE COMMITTEE**

TRO8

DISCLAIMER

UNITED STATES NUCLEAR REGULATORY COMMISSION'S

ADVISORY COMMITTEE ON REACTOR SAFEGUARDS

July 21, 2004

The contents of this transcript of the proceeding of the United States Nuclear Regulatory Commission Advisory Committee on Reactor Safeguards, taken on July 21, 2004, as reported herein, is a record of the discussions recorded at the meeting held on the above date.

This transcript has not been reviewed, corrected and edited and it may contain inaccuracies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES OF AMERICA
NUCLEAR REGULATORY COMMISSION

+ + + + +

152ND MEETING

ADVISORY COMMITTEE ON NUCLEAR WASTE

(ACNW)

+ + + + +

WEDNESDAY, JULY 21, 2004

+ + + + +

ROCKVILLE, MARYLAND

+ + + + +

The Advisory Committee met at 1:00 p.m. at the Nuclear Regulatory Commission, Two White Flint North, Room T2B3, 11545 Rockville Pike, B. John Garrick, Chairman, presiding.

COMMITTEE MEMBERS:

- B. JOHN GARRICK Chairman
- MICHAEL T. RYAN Vice Chairman
- ALLEN G. CROFF Member
- GEORGE M. HORNBERGER Member
- RUTH F. WEINER Member
- JAMES CLARKE Consultant
- BRUCE MARSH Consultant

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

ACNW STAFF PRESENT:

JOHN T. LARKINS, Executive Director

NEIL COLEMAN

LATIF HAMDAN

HOWARD J. LARSON, Special Assistant

MICHAEL LEE

RICHARD K. MAJOR, Staff

SHARON STEELE

NRC STAFF PRESENT:

DONALD COOL, Senior Advisor, Health Physics

Issues, Office of Nuclear Materials

Safety and Safeguards

YAWAR FARAZ, Project Manager, USEC

TIM JOHNSON, NMSS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

I-N-D-E-X

Integrated Safety Assessment Business 4

 Sharon Steele

Health Physics Related Issues 28

 Dr. Donald Cool

Adjourn 69

P R O C E E D I N G S

12:59 p.m.

CHAIRMAN GARRICK: Good afternoon, our meeting will come to order.

This afternoon, we're going to hear from Sharon Steele in spite of what it said on the program yesterday or whatever. And Sharon is going to talk to us about the integrated safety assessment business. She's going to give us a background briefing.

Sharon?

MS. STEELE: Thank you.

My name is Sharon Steel. I'm on rotation to the ACRS/ACNW, previously with Fuel Cycle and NMSS. And my introduction to integrated safety analysis and Part 70 in particular, came about through my review of the MOX Fuel Cycle facility. I've also had limited involvement in the ISC review of other fuel cycle facilities.

The presentation today is threefold. I would like to give background information, as Dr. Garrick said, on the new Subpart H requirement.

I also have an example of an ISA submittal that was made recently. And I'll share some recent developments in the ISA world for fuel cycle.

Well, when this slide was developed, it

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 was a new rule. Subpart H was developed in September
2 of 2000. New staff guidance had been identified and
3 basically they were NUREG-1520. I should say new
4 staff guidance was developed, which was the standard
5 review plan for the license application.

6 Also NUREG-1513 has guidance on integrated
7 safety analysis methodologies. But I also want to
8 point out that there are other applicable guidance.
9 NUREG-6410, which tells the applicant or the licensee
10 how to perform quantitative methods for determining
11 consequences.

12 The rule requires that by October of this
13 year, that the licensees complete their site-wide
14 integrated safety analyses and that they correct all
15 unacceptable performance deficiencies that they
16 identified through the ISA. And they also need to
17 submit their site-wide ISA Summary for the NRC
18 approval.

19 And Subpart H applies specifically to
20 nuclear fuel fabrication facilities and any new
21 enrichment facilities that will be coming in for --
22 with their applications.

23 The Part 70, Subpart H, regulatory concept
24 has three major elements, performance requirements,
25 items relied on for safety, and management measures.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 The focus of Subpart H is the integrated safety
2 analysis. And the applicant is required to identify
3 accident sequences and determine their likelihoods and
4 estimate consequences.

5 They do so in an integrated fashion by
6 using or convening a group of various safety
7 disciplines and they comply with the -- they help to
8 assure compliance with the performance requirements
9 which I'll get to in a second and identify the items
10 relied on for safety to prevent or mitigate accident
11 sequences and establish management measures that would
12 ensure that the IROFS are available and reliable.

13 As I said, here are the performance
14 requirements. This slide is really talking about
15 accident sequences that are determined to be of high
16 consequences.

17 And high consequences accidents sequences
18 must be made highly unlikely according to the rule.
19 And the high consequence accident is one where the
20 worker receives greater than 100 rem or some life-
21 endangering chemical exposure. It also applies to the
22 public. If the public receives greater than 25 rem or
23 an irreversible chemical injury.

24 Next slide. And if the accident sequence
25 is determined to be -- the accident consequence is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 determined to be of an intermediate result, then the
2 applicant must show that that accident sequence is
3 unlikely.

4 And in unlikely, the performance
5 requirements is that there is between 25 and 100 rem
6 for the worker, irreversible chemical injury. And for
7 the public, it's greater than 5 rem but less than 25
8 rem. And there's also environmental guidance.

9 Next slide. And this slide is just a
10 matrix to summarize or put it all together in one
11 page. Basically, as I said, high consequence events
12 must be demonstrated to be highly unlikely in order to
13 fall into the acceptable range.

14 And medium -- well, this says medium but
15 the terms is really intermediate consequence events
16 must be demonstrated to be unlikely in order to be
17 acceptable.

18 Next slide. One of the concerns is that
19 with this methodology that likelihood evaluation is n
20 not quantitative. Well, in the guide -- and the rule
21 does not require it to be quantitative. And in our
22 guidance, we have some qualities that we look for if
23 the applicant is going to use qualitative techniques
24 and quantitative techniques to determine likelihood.

25 If the applicant's definitions for

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 likelihood are qualitative, they would be found to be
2 acceptable if -- well, first of all, that criteria
3 must be reasonably clear and based on objective
4 criteria. And you must be able to differentiate
5 between a highly unlikely and an unlikely accident.

6 And basically you're looking at their
7 reliability and availability qualities related to the
8 IROFS that would be applied to those accident
9 sequences. And so you want to assure that these
10 measures or controls have a large -- provides for a
11 large margin of safety, there are low failure rates
12 associated with them.

13 You want to demonstrate a preference for
14 engineered, passive controls over administrative
15 controls. And insure that there's a high level of
16 quality assurance.

17 The controls must be auditable and have
18 surveillance measures that limit their downtime. They
19 must demonstrate defense in depth, a high degree of
20 redundancy, and a degree of independence diversity of
21 the controls. And they must be able to protect
22 against the vulnerabilities of common cause failures.

23 The rule also allows -- or the guidance --
24 the guides also allow to use a quantitative measure
25 for likelihood. And that guide, in particular, in is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 NUREG-1520. In 1520, it talks about high consequence
2 accident sequences where the -- it says that in order
3 to be acceptable, that that accident must occur less
4 frequently than 1 times 10 to the minus 5, for
5 example. And if it's to be unlikely, it must occur 1
6 times 10 to the minus 4.

7 Next slide. This is what the staff
8 generally expects from integrated safety analyses.
9 And essentially we would like -- we think it will end
10 up -- we'll end up with a streamlined process for
11 licensing.

12 And that the licenses can actually make
13 the facility -- would be able to make facility and
14 procedural changes without prior approval from the NRC
15 unless -- well, under certain conditions. And they're
16 listed there. You know, if the IROFS is not
17 downgraded and so on.

18 However, the licensees must submit
19 annually a summary of all such changes to the NRC.
20 And as a result, we hope that the annual summary
21 updates would significantly reduce the need for the
22 scope of the renewals.

23 I'm going to move on to the example of an
24 ISA submittal that we received. And this particular
25 one is the NFS Blended Low Enrichment Uranium or the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 BLEU Project. And I highlighted this portion of the
2 figure to just sort of -- to show where NFS would come
3 in.

4 Just by the way of background, NFS will be
5 receiving off-spec high enriched uranium materials.
6 And then they will down blend it into low-enriched
7 oxides, which will be sent to fuel fabrication
8 facilities for further processing.

9 And NFS submitted applications for the
10 BLEU Project under three different -- three major
11 parts. There's the Uranyl Nitrate building, which
12 will receive and store the materials.

13 Then the BLEU preparation facility, where
14 it will -- the actual down blending will occur. And
15 then there's an oxide conversion facility. And the
16 focus of this example is for the Uranyl Nitrate
17 building. And because it's a new process, even though
18 it's at an existing site, it's a new process, a new
19 building. Therefore, an ISA must be conducted.

20 And here are the overall steps that -- I'm
21 going to go through the steps or procedures that NFS
22 use and then actually show some of the results that
23 they came up with.

24 Essentially, they convened a team of 50
25 disciplines. And this team got together and performed

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 a process hazard analysis. But the method they
2 selected is called a HAZOP. And basically with the
3 HAZOP, it's a very systematic way of selecting nodes
4 and the processes and you use guide words to determine
5 whether you're going to be too high in a particular
6 area, too low, and so on.

7 So they performed the individual and the
8 specific analyses to identify the hazards and the
9 accident sequences. Then those accident sequences are
10 evaluated to see whether they meet the performance
11 requirements or not. And so they're binned. And that
12 part, as I may have mentioned before, is quantitative.

13 And then they categorized the likelihood
14 of each accident sequence. And they are using the
15 risk-index method, which is one method that was
16 demonstrated in the guidance document, NUREG-1513.

17 And based on the categorization of the
18 likelihood, they identify IROFS for each accident
19 sequence where you may have a consequence of concern.

20 Go ahead. So this is where they bin the
21 accident sequences. Once they've identified the
22 sequences from the HAZOP, they evaluate the
23 consequences and they bin them according to the
24 consequences. And this looks like one of the previous
25 slides so basically they're just getting high,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealgross.com

1 intermediate and low.

2 And like I said, it's the risk index
3 method so they bin them and then they assign a number
4 to that particular binning and so on. And the -- I
5 guess I did say the evaluation of those consequences
6 was based on quantitative methods in NUREG-6410.

7 To determine the initiate and frequency,
8 NFS proposed this indexing of assignments for the
9 initiating event frequency.

10 Basically they're saying for an accident
11 to be not creditable, that you cannot have more than
12 one failure per 100,000 years. So if something -- and
13 they assign a frequency index of minus five to that.
14 They use a frequency index of minus 4 for highly
15 unlikely. And minus 3 for unlikely.

16 Okay. Each IROFS is assigned an IROFS
17 failure index as specified in this table. And this
18 area is definitely a qualitative criteria for
19 likelihood. Basically they assign an index of minus
20 4 if you have a really robust control. And lots of
21 management measures to ensure availability. And a
22 zero of there is no protection.

23 They then calculate a total risk
24 likelihood and categorize it. And essentially they
25 add the initiating event frequency and the IROFS

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 failure IROFS failure frequencies that you saw in the
2 previous slides. And using this, it can demonstrate
3 the relative importance of IROFS. But then they
4 eventually use these categories in here to determine
5 acceptability of the particular control for the
6 accident sequence.

7 And this is similar to another slide you
8 seen before. But once they've come up with the
9 likelihood index T, here, and knowing the consequence
10 category bin, they can determine whether that accident
11 sequence and the sequence likelihood pair was
12 acceptable.

13 Okay. And unfortunately, the reproduction
14 is not so great on this screen. I think it might be
15 better in your handouts. But this is a matrix of what
16 they did for each node where there was a consequence
17 of concern. First -- I can't even read it -- they
18 assigned -- okay.

19 For the -- in Column 2 -- and Column 1
20 identifies the accident sequence and the node where it
21 occurs. And I'll just talk about the first row of
22 information. For the initiating event frequency, they
23 determined that there was an index of minus 3 if there
24 was a shipper error, where unsafe uranyl nitrate was
25 received in a particular vessel. And this accident

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 sequence from the HAZOP that was identified as one
2 where there was a high concentration of uranium in the
3 tank.

4 As a preventive measure, they do not
5 identify the IROFS in this particular document because
6 it's a nonproprietary version of the ISA summary. In
7 the version that the staff would have reviewed, we'd
8 see the IROF. But they did show that they assigned a
9 frequency index of one -- ten to the minus -- well, of
10 minus 1. And they added another preventive IROFS, and
11 that had a frequency index of minus 2.

12 There's no mitigation applied to this. In
13 fact, this is going to be a possible criticality
14 accident. And so the objective is to prevent rather
15 than mitigate.

16 They also show what the likelihood indices
17 that they would obtain if they controlled or did not
18 control the accident. And the last -- well, Column 9
19 shows the overall risk index for the particular
20 accident. And in this case, if it's controlled, the
21 final number is C equals 3. And that would mean that
22 that prevents an acceptable risk.

23 Next slide. And this is just more of the
24 same. And I believe they went through several -- I
25 don't know the total number of nodes but there were

1 many. I think it's over 30 that were identified as
2 consequences of concern. And they did that for all of
3 them.

4 And the next slide shows what they did for
5 natural phenomenon and external event hazards. And I
6 forgot to mention that they not only look at process
7 risks but they look at external events.

8 Some of the external events that they
9 looked at were seismic, high winds, flooding, and
10 lightning, and tornadoes, and pretty much determined
11 that they had sufficient controls and mitigating
12 factors to prevent those accidents from resulting in
13 exceeding the performance requirements.

14 This is just another part of the table
15 showing the natural phenomenon. And this document is
16 available in ADAMS.

17 In the end, NFS specified the various
18 IROFS controls. And they selected controls based on
19 a preference for passive over administrative. And the
20 management controls that they specified were applied
21 to the design, construction, operations, maintenance,
22 change controls of the IROFS.

23 And they planned to or they graded the
24 management measures commensurate with the level of
25 risk reduction.

1 And based on their evaluation, the staff
2 found that the management measures and IROFS would
3 make the credible intermediate consequence accidents
4 unlikely and high consequence accidents highly
5 unlikely.

6 Thank you. And that's it for the
7 particular example.

8 And so the next area I'm going to go into
9 is some of the recent developments that came about
10 based on -- well, I'm going to talk about the status
11 of licensing -- of ISA submittals. And then, also,
12 some outcomes of recent workshops.

13 There was a workshop in September of 2003
14 where stakeholders identified areas that were not
15 clear to them in the regulations or the guidance. And
16 staff came back and developed interim staff guidance
17 for the licensees to address those issues. All those
18 guidance documents are draft.

19 And then I'll talk about the recent
20 workshop that occurred in July to address the interim
21 guidance and issues from the previous workshop.

22 And this is the status of ISA summaries.
23 These are the ISAs. We received three -- well, we've
24 actually received three ISA summaries associated with
25 the BLEU Project from NFS. And -- however, we've

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 approved two. And we've approved the USEC -- the
2 pilot plant ISA summary.

3 There are also several ISA summaries that
4 are under review right now. And there are others that
5 are still out there that we're anticipating to receive
6 before October 18th, which is their deadline. And we
7 know that in the fall that we should get some
8 summaries from USEC and MOX, the USEC being the gas
9 centrifuge -- proposed gas centrifuge facility.

10 Okay. There were nine areas where interim
11 staff guidance is being considered. The first seven
12 are under development. They are a draft. And ISGs 8
13 and 9, which have to do with natural phenomenon hazard
14 and initiating event frequency are -- have not been
15 drafted as yet but I believe they will be drafted in
16 the future.

17 And this is the last slide. Just -- these
18 were the basic discussion areas during the July
19 workshop. And it sort of just maps over what some of
20 the interim staff guidance documents -- the areas that
21 are highlighted are in orange are really areas where
22 there were the most active discussions.

23 So unless you have any questions --

24 CHAIRMAN GARRICK: Yes --

25 MS. STEELE: -- that's it.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 CHAIRMAN GARRICK: -- we may have a few --

2 MS. STEELE: Okay.

3 CHAIRMAN GARRICK: -- although we have
4 looked at this in the past.

5 EXEC. DIRECTOR LARKINS: I --

6 CHAIRMAN GARRICK: Pardon?

7 EXEC. DIRECTOR LARKINS: -- sorry. I'm
8 sorry I missed the beginning of Sharon's presentation.
9 But I just wanted to give a little introduction.

10 The idea here was really -- for Sharon to
11 sort of give you some background because one of the
12 things that is on our current projected workload is to
13 review some of these fuel cycle facilities and in
14 discussing this with the staff, I need to get feedback
15 from you as to when you'd like to be engaged in those
16 discussions. And what types of topics.

17 In the interim, I've said basically when
18 the staff has completed their review and are getting
19 ready to issue a set of RAIs or whatever. But, you
20 know, any feedback.

21 This was hopefully to bring you up -- to
22 give you a status of what the staff is doing as a part
23 of their reviews. And give you a better
24 familiarization with the regulatory framework so you
25 can decide what it is and when you'd like to take a

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 look at these issues.

2 MR. LARSON: And it's only for those eight
3 facilities, right?

4 MS. STEELE: The fuel fabrication and the
5 future enrichment facilities, yes. The Part 70
6 licensees.

7 EXEC. DIRECTOR LARKINS: But we have three
8 of them which are coming up shortly. So that was sort
9 of the idea.

10 CHAIRMAN GARRICK: Well, as you know, when
11 we looked at the ISAs, integrated safety analysis
12 process before, one of the things we kept observing
13 was that we'd like to see one. We'd like to see how
14 new models are actually put together and executed.
15 And how they handle the information and the data and
16 what have you.

17 We're very familiar with process because
18 this is basically the process hazards analysis
19 approach used by the chemical industry. And it's used
20 extensively by other industries, including DOE. And
21 maybe they have refined it as much as anybody in
22 support of the safety analysis work that's done on
23 nuclear explosives.

24 So it clearly is an approach that has a
25 lot of experience and support. We have always had a

1 few problems with it because we preferred it moving
2 more in the direction of a quantitative approach. And
3 you have to do almost as much work here as you do for
4 a QRA, quantitative risk assessment.

5 And so the position of both the ACRS and
6 the ACNW, in the past, has kind of been we hope that
7 what this does do is -- that it is structured in such
8 a way that the option for moving towards a more PRA
9 format is not excluded.

10 And I would hope that that continues to be
11 the case because I think this is not risk oriented as
12 it could be if we were to do that.

13 I think that it would be useful for the
14 Committee to hear from an applicant, for example, a
15 presentation on how they have implemented the ISA
16 methodology. That's usually where you learn the
17 greatest amount just as you would if you were
18 listening to somebody presenting to you their PRA.

19 And as to timing, you know, that's -- the
20 sooner the better.

21 There are a couple of issues here that
22 caught my eye. And I think one is just a matter of
23 words.

24 You said in the opening remarks that this
25 was for fuel fabrication and enrichment facilities.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 But you weren't saying it to mean that it was -- you
2 included in that mix, I assume, process facilities.

3 For example, what about conversion
4 facilities like facilities that convert U-02 to UF-6.
5 I would assume the same methodology could be applied
6 there and would be. Is that not correct?

7 MS. STEELE: The conversion facility
8 you're referring to is the one we have in Metropolis?

9 CHAIRMAN GARRICK: Yes.

10 MS. STEELE: That one falls under Part 40

11 --

12 CHAIRMAN GARRICK: Yes.

13 MS. STEELE: -- license. And I don't know

14 -- I suppose they could do --

15 CHAIRMAN GARRICK: Well, what --

16 MS. STEELE: -- an integrated --

17 CHAIRMAN GARRICK: -- if the Allied
18 facility --

19 MS. STEELE: -- safety analysis --

20 CHAIRMAN GARRICK: -- and the --

21 MS. STEELE: -- but they're not required
22 to.

23 CHAIRMAN GARRICK: -- yes, if the Allied
24 facility and the Sequoia Fuels facility were still
25 operating, would they fall under this?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MS. STEELE: I believe there are Part 40
2 licenses -- they would have been Part 40 licenses and
3 they would not fall under this requirement.

4 CHAIRMAN GARRICK: Yes. And is there a
5 similar methodology?

6 MS. STEELE: Under Part 40?

7 CHAIRMAN GARRICK: Yes, under Part 40.

8 MS. STEELE: No.

9 CHAIRMAN GARRICK: I see. Okay.

10 I don't think I want to get into it very
11 much but there's some terms here that are kind of
12 bothersome.

13 MS. STEELE: Can I --

14 CHAIRMAN GARRICK: Yes?

15 MS. STEELE: -- can I address some of the
16 things that you talked about earlier? Before you --

17 CHAIRMAN GARRICK: Right.

18 MS. STEELE: -- continue with the next
19 question?

20 Just for the benefit of others, the
21 guidance document, 1520, does not preclude the use of
22 a PRA-type --

23 CHAIRMAN GARRICK: Yes.

24 MS. STEELE: -- method. And, in fact, if
25 there are complex processes, it would guide one to use

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 perhaps event trees or something more sophisticated or
2 complicated than a HAZOP methodology.

3 CHAIRMAN GARRICK: Yes.

4 MS. STEELE: And I don't know in terms of
5 hearing from a future applicant, I know right now we
6 have in the room project managers for the LES and the
7 USEC facilities. And I don't know what the status is
8 of those ISA summaries are but would the Project
9 Managers care to comment?

10 MR. JOHNSON: I'm Tim Johnson. I'm a
11 Project Manager for Louisiana Energy Services. As
12 part of the application, LES did submit an ISA
13 summary, which is under review. We haven't completed
14 the review yet. But they used a semi-quantitative
15 method using the risk index method that was suggested
16 in the standard review plan.

17 CHAIRMAN GARRICK: Thank you. Thank you.

18 MS. STEELE: And Yawar was going to -- the
19 Project Manager for USEC is going to --

20 MR. FARAZ: I'm Yawar Faraz. I'm the
21 Project Manager for USEC.

22 We did review their lead cascade
23 application, which was submitted a year and a half
24 ago. And we approved it last February, issued a
25 license. And they also had submitted an ISA summary

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 for that facility using a risk index method.

2 We're expecting an application from USEC
3 for their commercial plant next month.

4 CHAIRMAN GARRICK: Okay.

5 I just am reminding myself that I don't
6 know how much interaction there is between the NRC and
7 other agencies and organizations that employ this
8 basic methodology but I think there would be a real
9 advantage in taking full advantage of other people's
10 experience.

11 I know in the nuclear explosive field,
12 they have developed this general PHA approach to a
13 pretty fine level. And it goes through exhaustive
14 review in the review process. And that's something
15 you may want to look into because they do a very
16 similar kind of modeling.

17 Is there any comments? George, have you
18 got any comments?

19 MEMBER HORNBERGER: No, I don't.

20 CHAIRMAN GARRICK: Ruth?

21 MEMBER WEINER: Only that like you, Mr.
22 Chairman, I'd like to see one done. I think it would
23 be very instructive.

24 CHAIRMAN GARRICK: Yes.

25 Allen?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MEMBER CROFF: Nothing additional.

2 CHAIRMAN GARRICK: Okay. Okay. I guess -

3 -

4 EXEC. DIRECTOR LARKINS: Well, one of the
5 things I think we need to do and in terms of planning
6 and as we request the staff briefings on these
7 particular facilities to see if the applicant would be
8 willing to come in and discuss their submittal. I
9 don't know right now. We'd have to ask and see.

10 CHAIRMAN GARRICK: Well, I think that's --
11 that would be the most revealing would be to hear from
12 the modelers. And see how they are inputting the
13 information, where they're getting their information
14 from.

15 The likelihood calculations are
16 particularly important, are of particular interest.
17 Because that is the important stepping stone towards
18 any quantitative or semi-quantitative approach. And
19 how they structure their accident sequences, their
20 basic scenarios.

21 So that's the thought there is that if we
22 really want to -- and we felt this way a couple, three
23 years ago. And at one time were going to get
24 somebody, I think it was from Lynchburg, was going to
25 come in and give us a briefing on how they put their

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 model together. So I think that interest still is
2 there.

3 And I think it would be the single event
4 that would bring the Committee closer to appreciating
5 and gaining confidence in the methods.

6 MR. LARSON: This would be one of the
7 things the Committee would look at, I guess, in its
8 retreat. And try to prioritize it along with the
9 other things --

10 CHAIRMAN GARRICK: Sure.

11 MR. LARSON: -- that it's going to look at
12 over the next year.

13 CHAIRMAN GARRICK: Sure.

14 EXEC. DIRECTOR LARKINS: Well, I think
15 we're scheduled in October to have a briefing of LES
16 or USEC -- one of them.

17 MR. LARSON: I think it's USEC.

18 EXEC. DIRECTOR LARKINS: Yes. So --

19 MS. STEELE: Is that right? Yawar, do you
20 know?

21 MR. FARAZ: Pardon?

22 MR. LARSON: October is USEC licensing
23 steps. They didn't say they'd go beyond that like
24 bringing in the --

25 EXEC. DIRECTOR LARKINS: Okay.

1 MR. LARSON: -- applicant. But we can
2 ask.

3 CHAIRMAN GARRICK: Any questions from
4 staff?

5 (No response.)

6 CHAIRMAN GARRICK: Okay. Thank you very
7 much, Sharon.

8 MS. STEELE: Thank you.

9 CHAIRMAN GARRICK: We're a little ahead of
10 schedule, which is good, because we've got a lot of
11 report work we want to do a little later.

12 VICE CHAIRMAN RYAN: Dr. Cool is here.

13 CHAIRMAN GARRICK: Okay.

14 So the next item on our agenda is Health
15 Physics issues. And the Committee lead person on
16 those issues is Dr. Michael Ryan. And I'll let Mike
17 lead the discussion.

18 VICE CHAIRMAN RYAN: Thank you very much,
19 Mr. Chairman.

20 Good afternoon.

21 Good afternoon, Dr. Cool, how are you?

22 DR. COOL: Just wonderful. Thank you.

23 VICE CHAIRMAN RYAN: Well, that's great.

24 We're going to hear from Dr. Cool on
25 Health Physics related issues. And I think, in

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 particular, we're going to focus on the consultation
2 papers of the ICRP that are hot off the press.
3 Welcome.

4 DR. COOL: Thank you and good afternoon.
5 We'll see if we can get this -- I know the light
6 concept there on the screen. In all due course,
7 something should magically appear via the electronics.

8 I'm Dr. Donald Cool. I'm the Senior
9 Advisor for Health Physics Issues in the Office of
10 Nuclear Materials Safety and Safeguards.

11 After talking with Mike several times over
12 the last few months, we agree that it would be useful
13 at this stage in the process to provide you with an
14 information briefing on some of the things that are
15 going on, in particular, the activities of the
16 International Commission on Radiological Protection,
17 ICRP.

18 What I'm in hopes to do very briefly for
19 you today is give you just a bit of background on
20 where NRC currently is in its radiation protection
21 standards, a very brief, very high level overview of
22 the draft ICRP recommendations that have come out, and
23 then some of the next steps that we envision over the
24 next few months as we begin this examination.

25 So we're already on the background slide.

1 Let's leave it there. Thank you.

2 Just to reacquaint you with where we are
3 in the process, NRC revised 10 CFR Part 20, the basic
4 standards for radiation protection, finally getting it
5 published in 1991. That rulemaking took 12 years to
6 go through the process. It actually was implemented
7 in 1994. So that had a fairly long gestation cycle as
8 we went through the process.

9 During that intervening period, not
10 surprisingly, other things continued to proceed
11 forward. ICRP published a revised set of
12 recommendations, Report 60, in 1991. Now obviously
13 the staff did not have that report available to it at
14 the time that we actually promulgated Part 20.

15 So the NRC regulations are based on the
16 older set of ICRP recommendations that were
17 Publication 26 and the metabolic models that were in
18 ICRP Publication 30.

19 We did have the advantage of knowing a few
20 things about what were coming out. So, for example,
21 the public dose limit that is contained in Part 20 was
22 what actually came out for the first time formally
23 from ICRP in Publication 60.

24 There were a number of other things that
25 we didn't have accounted for within that process. So,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 as a result, we are a step behind the international
2 recommendations as we've proceeded forward.

3 I say that with all due caution because we
4 have taken on a case-by-case basis a look at proposals
5 by various licensees to use updated models, to use
6 effective dose from external exposure, and some of the
7 other things that have come about over the last 15
8 years of so and, in fact, approved them on case-by-
9 case basis.

10 We went to the Commission specifically for
11 their approval to move forward and do that on a case-
12 by-case basis. It's particularly useful for some of
13 the folks who are dealing with uranium or thorium and
14 some of those isotopes where the more recent metabolic
15 models actually indicate a lower risk per unit of
16 intake activity than had previously been modeled.

17 The more you know about the model -- the
18 body, things move up and down. Some things move down
19 and licensees, not surprisingly, wanted to take some
20 advantage of that in their modeling approach. So
21 that's where we are on that part.

22 Go ahead and have the next slide. Thank
23 you.

24 In 2001, the staff went to the Commission
25 because we knew things were coming along. It seemed

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 like more than enough things had transpired. There
2 were some scientific issues that we were aware of to
3 proceed with the next steps.

4 Included in that approach was a no action
5 alternative, to go ahead and begin rulemaking at that
6 time, and try to work in parallel with ICRP or to sit,
7 monitor closely, but wait for the ICRP recommendations
8 to come out before firmly engaging in a process. The
9 staff actually recommended that third option and that
10 is what the Commission approved.

11 So that is what we have been doing over
12 the last several years.

13 More recently -- next slide -- there we go
14 -- two papers have gone up from the Office of
15 Research, close coordination between Research and NMSS
16 and others. The first was responding to the
17 Commissions's request that we have some proposals for
18 a more robust materials program.

19 When I say materials in this context, I do
20 not mean the properties of metal, as you are often
21 used to look at in the reactor forum, but byproduct
22 and source material and all of the other things that
23 we also have regulatory jurisdiction over.

24 And then a month or so after that, we also
25 provided a paper outlining some recommendations for

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 how to evaluate scientific recommendations relating to
2 health effects in radiation biology and the ICRP
3 recommendations.

4 The Commission has given us SRMs just in
5 the last couple months which approved both of those
6 plans, told us to go ahead and move forward with a
7 more aggressive and proactive approach in looking at
8 some of the science and activities.

9 They warned us to stay away from too much
10 in terms of protection of the environment. I will
11 talk briefly about that in a few minutes so let's
12 return to that topic.

13 And so we are now engaged actively in the
14 process of looking at the ICRP recommendations. And
15 in an ongoing process, in looking at the variety of
16 other things, the BEIR 7 work that is ongoing, looking
17 at the radiation risk relationship, DOE's low dose
18 study efforts, the new results that have been coming
19 out of Hiroshima and Nagasaki and the updated
20 dosimetry.

21 There's a lot of different activities that
22 are going on at this particular junction in time.

23 Let's go ahead with the next slide. In
24 keeping with that, we have been aggressive in trying
25 to pursue opportunities to interact with ICRP. We

1 have provided comments directly back to the ICRP both
2 on a draft proposal that they had on protection of the
3 environment and on an early white paper of concepts
4 which they had on the general recommendations.

5 We've availed ourselves of almost every
6 opportunity we could to go to various forums and
7 discuss them internationally and nationally. And
8 tried to provide a variety of places where we could
9 input and influence the direction that things were
10 proceedings.

11 Let's go ahead to the next slide. ICRP
12 has been engaged in this development cycle for
13 probably five years or more, starting with some early
14 ideas that were floated by ICRP Chairman Roger Clarke,
15 discussed in two consecutive now IRPA, International
16 Radiological Protection Association meetings in
17 Hiroshima and more recently in Madrid, a variety of
18 different activities.

19 Some of the ideas initially floated were
20 very interesting and certainly got our attention
21 because they would have caused just a bit of concern
22 and heartburn were they to have gone all the way
23 potentially to fruition. And we have attempted to
24 move those. As I will describe in a few minutes, I
25 think we've been successful in those.

1 ICRP has formally placed the draft of its
2 recommendations on their website, www.icrp.org.
3 Download the file. It's about a two megabyte file.
4 Give yourself plenty of time on the printer because it
5 prints very slowly, 80-something pages long.

6 They will be accepting comments through
7 the end of this year, through December. So we have
8 now the next six months or so in which to examine and
9 provide feedback to ICRP.

10 Let's go ahead and move to the next slide.
11 These next few slides are a very quick overview of
12 some of the key items that are in the draft ICRP
13 recommendations.

14 At this point, I'm not going to give you
15 any staff views. We're only beginning the process of
16 trying to assemble those. I'll talk about how we're
17 going to be doing that when I finish giving you that
18 overview.

19 First and foremost, ICRP is placing yet
20 more focus upon the individual in the context of their
21 recommendations. So, in fact, first they talk about
22 protecting the individual from a particular source of
23 radiation, that via what they call the dose
24 constraint, the differences between constraint and the
25 limit. A limit, in ICRP language, is that which would

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 apply to all of the exposure that I could receive, as
2 an individual, from any of the variety of sources that
3 might be around me.

4 A constraint would be the value that you
5 would ideally place on that particular source with
6 respect to how much exposure that I could get from it.
7 So there is an all-source approach and there is a
8 specific approach limits and constraints.

9 ICRP has moved forward to try and simplify
10 the number of constraints they had. If you go sorting
11 through the various documents that have been published
12 over the last 15 years, you can come up with some 30-
13 plus different constraint recommendations for
14 different specific situations that are contained in
15 those ICRP publications.

16 I'll talk about specifically what those
17 values are in a minute. One of the places that they
18 had initially made a proposal was to eliminate
19 entirely limits from the recommendations. There was
20 a great deal of push back from, interestingly, both
21 the industry and the regulators, saying that there was
22 a place for limits.

23 There were certain places where you had to
24 have legal requirements and otherwise. And they have
25 retained that recommendation within this draft

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 proposal.

2 Numerically, the values for limits are
3 exactly the same as they were in ICRP's Publication
4 60, that is for occupational exposure, 10 rem over
5 five years, in other words roughly two rem per year,
6 with a maximum of 5 rem in any year. Five rem is the
7 value that we currently have in Part 20 for
8 occupational exposure.

9 For public exposure, the limit is set at
10 100 millirem per year, which is exactly the same as we
11 currently have in Part 20.

12 Let's go ahead to the next slide. ICRP
13 does not use background to justify it's
14 recommendations for various dose levels however they
15 have used it as a benchmark and to try and establish
16 the various levels of concerns which people would
17 typically tend to have for varying degrees of exposure
18 so as to try and rationalize an entire framework of
19 various kinds of exposures.

20 This graphic is taken from the ICRP Draft,
21 fairly readable actually. In the middle, natural
22 background, roughly one millisievert per year that is
23 excluding all of the radon contributions so this is
24 the natural terrestrial gamma radiation, the cosmic
25 radiation, those sorts of things, the potassium 40 in

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 our body, one millisievert, 100 millirem, all of these
2 slides are in the SI units. I'll try to do the
3 conversions for you if you need.

4 Moving below that, there tends to be a
5 lower degree of concern down to the point where
6 basically no one does much of anything to actually
7 influence it if they have choice in the matter. Above
8 that, you get increasing levels of concern up to the
9 point where you almost always do something one way or
10 another.

11 If we can go to the next slide, that
12 translates for ICRP then into four maximum constraint
13 values, 100 millisievert, that's 10 rem, for
14 emergency-type situations as in what you would
15 normally want to try and hold workers to in an
16 emergency situation responding expect for, perhaps,
17 lifesaving-type measures where you're almost always
18 assured of doing evacuation or a variety of things of
19 things if you are in emergency response, where people
20 will almost always try to do something to control
21 ongoing exposures that they might find in the
22 environment.

23 The second maximum constraint, 20
24 millisieverts, that's two rem, each of these are
25 annual values, by the way -- that's typical for a

1 direct or indirect benefit of the exposed individual,
2 most usually occupational exposure.

3 It assumes that there is some measure of
4 training and understanding and ability to influence
5 the degree of exposure you're getting, minimize you
6 exposure when possible.

7 And in the public side, places where you
8 would apply simpler countermeasures, some of the
9 things like perhaps iodine prophylaxis, the place
10 there you would usually try to shelter people in an
11 emergency situation, so of those sorts of things.

12 The third maximum constraint, one
13 millisievert per year, that's 100 millirem, that's for
14 situations where the practice or situation probably
15 has some societal benefit. But there's no expectation
16 of training or monitoring or other values, in other
17 words, public exposure.

18 That is a maximum value assuming a single
19 source although not in ICRP's table, in the text of
20 the draft recommendations, they have an additional
21 little caveat that if there are multiple sources of
22 significant contribution, then the constraint should
23 probably be beyond the order of .3 millisieverts, 30
24 millirem. That's the international rounding version
25 of what we usually do at 25.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 Margin of error is essentially nonexistent
2 between those two.

3 The final number, the minimum constraint,
4 the minimum number that they would ever suggest
5 anybody attempt to use as a constraint for a single
6 source. I will not use the old famous acronym but it
7 has had its various lingo in NCRP at the negligible
8 individual risk level.

9 People talk about trying to have clearance
10 or controlling materials, exclusion exemption, a
11 variety of other sorts of things that go on at that
12 level.

13 That does not mean that an effort to
14 reduce exposures under the ALARA principle couldn't
15 take it or perhaps shouldn't take an exposure below
16 that level. This would just be the lowest value that
17 they would ever suggest someone selecting to start
18 that process.

19 Because that is, in fact, the way they see
20 a constraint, the maximum value source to an
21 individual, within which you then provide additional
22 protection -- next slide -- to compliment that
23 constraint with the requirement to optimize
24 protection.

25 This is ALARA. This is the second

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 cornerstone of radiation protection. This has not
2 changed in any significant extent from that which we
3 have seen before, which is currently part of Part 20
4 in other activities.

5 The third leg, which everyone is typically
6 familiar with in the radiation protection scheme is
7 called justification, as in when should you even allow
8 such a source to be in existence.

9 ICRP's draft recommendations this time
10 back away from many of the statements that they said
11 with regards to justification. This is a clear
12 acknowledgment that in most all cases, radiation
13 protection decisions, the amount of radiation
14 exposure, the efforts that you can pursue, are
15 actually only one of many components that go into
16 deciding whether or not to have a particular source in
17 use.

18 And so justification, in the sense of
19 deciding that you're going to introduce a source, goes
20 well beyond the radiation protection recommendations.
21 They still suggest that it is important to have that
22 benefit, where appropriate, that radiation protection
23 considerations be a very strong component.

24 But they have backed away from some of the
25 language which could have been interpreted as you must

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 only focus on the radiation protection without
2 considering all of the other things that would go on
3 in the process.

4 Let's go ahead and move on to the next
5 slide. There are a number of other things that are
6 happening in these drafts. Some of these are actually
7 perhaps more significant, the changes that we might
8 wish to make.

9 Some of the most significant ones, there
10 are proposals that change both the radiation weighting
11 factors and the tissue weighting factors in the
12 calculation of the effective dose. In the radiation
13 weighting factors, protons and electrons continue to
14 be one. That's not surprising.

15 Protons are a two. That's just a little
16 bit of a change there.

17 Alpha particles are 20. That's what we've
18 expected.

19 And you have a curve -- I haven't tried to
20 reproduce all of this data for you -- for neutrons.
21 Amongst other things, this revised curve has the
22 effect of lowering the weighting factor for low-energy
23 neutrons to a lower level.

24 So that would have some effect where you
25 are calculating neutron doses. We don't do a whole

1 lot of that here but for some folks, that gets to be
2 more important.

3 The tissue weighting factors have also
4 undergone a rather substantial revision. They have
5 lumped them into four categories. Interestingly,
6 breast has moved up to .12, so an increased risk
7 associated with irradiation of the breast. Lung has
8 remained the same. Bone marrow and others at .12.

9 The gonads have moved down to .05. Recall
10 that they used to be .25. There was a much greater
11 concern about exposure of the gonads being driven by
12 a lot of the concerns of genetic susceptibility and
13 genetic risk.

14 The material that's now available
15 indicates that that risk is not nearly as significant
16 as it was previously believed. And so that has
17 resulted in a rather substantial reduction in the
18 contribution for the gonads. Hence the weighting
19 factor comes down.

20 There are a few other little changes that
21 go on. There are a set of remainder tissues, a fairly
22 long list of them, which would be lumped together and
23 averaged in order to complete the calculation.

24 So there are a number of things that have
25 happened in the scientific underpinnings of the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 calculation that we would want to look at. Any time
2 you play with the equation and you play with factors,
3 obviously you have people very nervous about what dose
4 they now calculate for what they thought was the same
5 exposure that they were doing before.

6 And, in fact, some of this means that
7 depending on your favorite radio nuclide, the exact
8 same amount of material under the new calculations may
9 be a lower effective dose or it may be a higher
10 effective dose. And it will move around both ways.

11 I don't have anything like a complete
12 list. There's 800 and something radio nuclides out
13 there to look at.

14 Some other interesting factors. The fatal
15 cancer risk coefficient itself increases just
16 slightly. But the overall detriment coefficient
17 actually comes down some in this calculation.

18 Neither one of them are substantial enough
19 to cause any significant change in the way we've been
20 doing business. When you round up the one significant
21 figure, you're still in the same place but there are
22 small changes in each direction looking at how they
23 would do that calculation.

24 They've spent a fair bit of time in the
25 draft talking about patient dose, the justification

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 and optimization of patient doses, something that the
2 NRC doesn't directly get involved with other than to
3 make sure that the physicians prescription is required
4 but very, very important in other forums and
5 activities.

6 And they have included for the first time
7 a policy on protection of nonhuman species as in the
8 protection of the environment.

9 Let's go on to the next slide. This is an
10 area that ICRP is devoting a great deal of additional
11 attention to. There was a separate publication,
12 Publication 91, that came out not quite a year ago,
13 which laid out this framework.

14 So in the draft recommendations that were
15 just published, there's nothing new that you can't
16 find in ICRP Publication 91 that came out last
17 October. ICRP plans to have a new Committee 5 dealing
18 particularly with this issue when it starts its next
19 term, its 2005 to 2009.

20 And they currently have a task group that
21 is moving a step beyond the Publication 91 work and
22 actually trying to develop a set of reference flora
23 and fauna. And yes, you interpret that correctly.

24 It's the reference pine tree, frog,
25 there's about a dozen. I'm not going to try and quote

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 them all off to you but there are a variety of
2 different plants and animals to represent not the most
3 sensitive but something which could be a benchmark for
4 helping to understand how various modeling and
5 benchmarks and evaluations take place.

6 At this point in the process -- you can go
7 ahead on to the next slide, thank you -- the second
8 tick is their statement with regards to protection of
9 the environment. They have attempted to construct a
10 sort of parallel approach so that it would be
11 safeguarding the environment by reducing frequency of
12 the effects likely to cause early mortality, reduced
13 reproductive success.

14 Note that this is a different kind of
15 endpoint than you look at with humans. In humans,
16 you're trying to prevent any deterministic effects and
17 you're trying to minimize the stochastic doses.

18 In the protection of the environment,
19 you're looking at a different set of endpoints, a
20 higher level set where you're trying to reduce early
21 mortality or reproductive success.

22 So that's the goal that they have laid
23 out. There's still quite a bit that will need to be
24 evaluated to try and move farther.

25 We can have the next slide. As I think

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 was in the SRM that the Commission gave the Committee
2 not that long ago, the Commission has also given us a
3 very clear message and transmitted this message to
4 both the ICRP and the IAEA.

5 To quote the Chairman, this is a quote out
6 of our SRM, "The Commission continues to have deep
7 misgivings about the need to go forward with
8 standards."

9 So we are watching this very closely to
10 try and influence it in the correct direction. Quite
11 frankly, there is a huge amount of work that needs to
12 be done simply to understand the underlying science,
13 to understand the modeling methodologies that are
14 currently available, to try and have some benchmarking
15 consistency with the way different people do it across
16 the United States, Europe, and other places before
17 there could be any sort of consideration of whether a
18 standard is necessary, what that might look like, and
19 otherwise.

20 And that's a great part of what the
21 Commission is concerned about is it doesn't appear
22 that it is necessary. Certainly there is a conceptual
23 gap that needs to be filled. But let's not go running
24 off to try and write a new standard.

25 We've taken and are continuing to take the

NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 position that the framework in process should allow
2 flexibility, let people look at it and move forward
3 carefully.

4 That is the very, very quick summary of
5 the ICRP recommendations. If we can go to the next
6 slide -- I have been having conversations with Roger
7 Clarke, who is the Chairman of ICRP and Lars-Erik
8 Holm, who is the Vice Chairman, for literally months
9 now, trying to find a mutual date by which they could
10 come over and visit us in the United States for a day
11 or two and talk about this.

12 I think perhaps we're actually going to
13 make it in September, roughly the middle of the month.
14 The plans and details are not all completely laid out
15 yet but it appears that they will be in town the 14th
16 and 15th of September. Now all of this, of course, is
17 still subject to change but I think they've bought
18 some tickets so it's becoming a little more firm.

19 I believe they plan to have meetings with
20 each of the Commissioners.

21 We are trying to arrange an opportunity
22 for the various federal agencies through ISCORS, the
23 International Steering Committee on Radiation
24 Standards, to have a time of interaction.

25 And to see if we can arrange an

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 opportunity for them to spend a few hours in a public
2 forum because certainly there are lots of people in
3 the area as well as NEI and a variety of other
4 industry groups who are also in the D.C. area who
5 would very much like that interaction.

6 Those details are not worked out so I
7 can't tell you anything more than I'm pretty sure they
8 are coming. I expect it to be -- the 15th would be
9 the day in which we might be able to arrange those but
10 no other arrangements have been made yet.

11 If we can have the last slide. There are
12 a variety of reviews that have now been started.
13 Certainly within the NRC staff, we have begun that
14 process. Our office-level steering committee on
15 radiation protection will be meeting next week to try
16 and lay out the details of how we're going to pull
17 that together and assemble a coherent set of comments
18 within the NRC staff.

19 In addition to that, they ISCORs,
20 Interagency Steering Committee on Radiation Standards,
21 Federal Guidance Subcommittee, will be coordinating an
22 interagency federal review. We have a meeting
23 tomorrow to kick that process off to try to lay out
24 some of the framework and ideas.

25 We also will have an opportunity to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 interact, as well as EPA and DOE, as members of the
2 Nuclear Energy Agencies' expert group that will be
3 providing comments. That will be an international set
4 of comments that will be assembled.

5 So there will be a whole series of forums
6 in which we attempt to try and put forward comments
7 and ideas. The staff plans, at this point very
8 tentative, are to try and have a coherent set of
9 comments within the NRC for Commission consideration
10 by early in October, roughly the first of October, to
11 allow plenty of time for interactions and for the
12 Commission to be able to agree and provide a set of
13 comments to ICRP.

14 That will also enable us to have a
15 Commission-agreed position as we interact with some of
16 these other organizations a little bit later in the
17 year.

18 We are in hopes that we can interact with
19 you during that process. Things will come together
20 fairly nicely in the mid-September time frame to see
21 where the staff reviews are, get some interaction with
22 ICRP itself, and be able to pull together some ideas.

23 And that completes the very quick
24 overview. And I would be glad to entertain your
25 questions. Thank you.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 VICE CHAIRMAN RYAN: Thanks. That was, I
2 think, a good, thorough, yet top-level briefing but
3 gives us a picture of where things are.

4 I guess I'll wait and see if other
5 Committee members have questions first. And then
6 maybe we can have a little bit more detailed
7 discussion.

8 I'll start with Allen.

9 MEMBER CROFF: I think only my
10 congratulations on a very lucid presentations. I
11 don't have any further questions.

12 VICE CHAIRMAN RYAN: Ruth, any questions?

13 MEMBER WEINER: I'd like to add my thanks.
14 I thought that was a very interesting presentation.

15 I do have a couple questions. One of them
16 refers to the change -- I'm trying to find --
17 desperately to try to find the slide that I want to
18 talk about -- on your Slide 11?

19 DR. COOL: Yes?

20 MEMBER WEINER: You said the fatal cancer
21 risk coefficient increases and the total detriment
22 risk decreases. As we're uncomfortably aware, that
23 fatal cancer risk coefficient is simply used as a
24 linear conversion factor. And everybody says oh, my
25 goodness, here is the dose in person rem. Now you're

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 going to get so many cancers.

2 Is there -- this is really more a comment
3 than a question but is there some way that you can
4 convey to the public -- we sit here and make sensible
5 statements.

6 Is there some way you can convey to the
7 public that this is the sense of this particular
8 bullet, that you aren't then going to have, you know,
9 radiation isn't worse than we thought or whatever?
10 That this is not even a totally appropriate use of
11 this coefficient? Is there some way that that can be
12 conveyed and sort of disseminated generally?

13 DR. COOL: I think there is. There's
14 probably several ways to do it. And we could
15 brainstorm about them. That would make a wonderful
16 conversation or multiple conversations.

17 You're quite right. There are several
18 things in this. ICRP does, for pragmatic purposes in
19 making its recommendations, assume that there is a
20 linear relationship between the dose and the risk that
21 is associated with it.

22 When you start to tease into that just a
23 little bit, one of the first things -- Abel Gonzalez's
24 graphics are some of the best, where he immediately
25 points out to you first and foremost, I'm starting at

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 100 millirem because that's where background is --

2 MEMBER WEINER: Yes.

3 DR. COOL: -- and above that, we assume
4 that there is this proportionality. There is a high
5 degree of sensitivity to the fact that there is simply
6 no absolute information that is available about what
7 happens at very small increments of dose.

8 We are living in an environment which has
9 radiation in it. It's always changing.

10 These materials that are here imply a
11 great deal of precision, which, of course, isn't
12 really warranted when we actually start talking about
13 what might happen to me or what might happen to you if
14 you got a particular exposure because simply the
15 variability that each of us have is an enormous factor
16 compared to some of these.

17 What I've given you today is sort of the
18 scientific, of course, view in this sort of
19 discussion. When you start to interact with the
20 public, you need to say it in a number of different
21 ways to try and represent it in a way that they can
22 understand it.

23 MEMBER WEINER: I thank you for the
24 starting at 100 millirem comment.

25 My other question has to do with Slide 13

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 which is -- yes, this second bullet. Our experience
2 at the DOE sites, like Hanford, Savannah River, Sandia
3 where I work, is that the environment flourishes in
4 the absence of human activity --

5 DR. COOL: Yes.

6 MEMBER WEINER: -- no matter what kind of
7 radiation the environment is exposed to. I know --
8 and I was going to ask you -- I know of no data that
9 shows that given all of the other influences on the
10 natural environment that exists, that there is any
11 correlation between ionizing radiation exposure and
12 reproductive success, conservation of species,
13 maintenance of biodiversity, and all of these things.

14 Is there any such data that you can rely
15 on? And if there isn't, why is this going ahead?

16 DR. COOL: Well, let me answer the first
17 question is I'm not aware of any. That's the first
18 part of your question.

19 The second part of your question, I would
20 go back, and I can't quote ICRP's Publication 91, but
21 they, in fact, acknowledge that they do not believe
22 that there is an issue where the environment is not
23 being protected. But in the face of the increased
24 environment awareness in a variety of activities by
25 lots of our friends out there, it is difficult to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 sustain a simple statement that if you have protected
2 man, you have de facto and automatically protected the
3 environment.

4 In fact, it appears that the set of
5 protections that are put in place in order to provide
6 protection of man has protected the environments at
7 any place that we can measurement hence exactly your
8 statement.

9 But you don't have a demonstrable basis or
10 any sort of standing or correlated methodology to be
11 able to see how much radiation is actually in a
12 particular area to be able to provide some better
13 demonstration than what people take as a sort of
14 hortatorical of course because they no longer believe
15 that these days.

16 So this is really more to fill that, as
17 they put it, conceptual gap. And complete a framework
18 and provide a benchmark demonstration set so that when
19 someone comes up to you and says how do you know? You
20 can say we have all these data. They have not shown
21 these effects.

22 Here are some benchmark methodologies that
23 shows you here's what the dose is in this environment.
24 That dose is less than this. Therefore, we make the
25 statement.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 That is the place that we would hope to
2 get to. And why we would hope that, in the end, you
3 wouldn't need other standards. You wouldn't need to
4 take changes to effluent controls or otherwise.

5 VICE CHAIRMAN RYAN: Just so we're clear,
6 though, when you say we, you don't mean the NRC. You
7 mean the --

8 DR. COOL: I don't mean the NRC.

9 VICE CHAIRMAN RYAN: -- ICRP --

10 DR. COOL: -- I mean we in the really big
11 sense.

12 VICE CHAIRMAN RYAN: I got you. Okay.

13 MEMBER WEINER: We, in the scientific --

14 DR. COOL: We in the scientific sense in
15 keeping with the same statements here. Yes, thank you
16 for that --

17 MEMBER WEINER: Well, I would suggest --

18 DR. COOL: -- correction.

19 MEMBER WEINER: -- that if you're in any
20 way connected with any research that is going on in
21 this area, I would suggest a good place to look for
22 effects is, in fact, the defense facilities, the large
23 defense facilities both in the United States and
24 elsewhere. Because it is extremely evident there that
25 the more you keep people out, the more the environment

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 flourishes and that swamps everything else.

2 DR. COOL: I very much agree. In fact, I
3 believe that DOE with some of the RESRAD biota
4 calculations and examinations are going to be
5 participating in some of the benchmark activities that
6 the EC and NEA are conducting. So I think that is
7 going to be happening.

8 MEMBER WEINER: Thank you.

9 VICE CHAIRMAN RYAN: George?

10 MEMBER HORNBERGER: Well, actually, I also
11 had a comment on the bugs and bunnies. It actually
12 strikes me as quite strange because your endpoint, as
13 you point -- as you indicate, are different. So we're
14 not talking about individual protection.

15 And once we're not talking about
16 individual protection of pine trees, how are you going
17 to have an effect? How are you going to possibly have
18 an effect on reproductive success of a species?

19 Well, the only thing I can think of is a
20 very restricted environment where you have the
21 Tennessee snail darter existing only in one stretch of
22 the Clinch River. And you somehow introduce radiation
23 there an nowhere else. Is that the thinking?

24 I can't quite get my arms around that.

25 VICE CHAIRMAN RYAN: It sounds like deep

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 misgivings to me.

2 (Laughter.)

3 DR. COOL: Yes, deep misgivings, which we
4 share with you.

5 In fact, the thinking -- how do I put this
6 in a somewhat politically correct manner -- is still
7 evolving. You have pointed out some very good and
8 appropriate problems that are faced in trying to
9 develop this sort of framework.

10 And it's going to be very interesting in
11 the Chinese proverb sense of may you live in
12 interesting times, to see how this might proceed
13 because there are enormous issues of how you would
14 conduct measurements, how you would have any degree of
15 understanding.

16 And you're dealing with very complex
17 systems and --

18 MEMBER HORNBERGER: But even conceptually
19 --

20 DR. COOL: Right.

21 MEMBER HORNBERGER: -- even conceptually
22 how can I think about having an effect on the
23 reproductive success of pine trees?

24 VICE CHAIRMAN RYAN: George, if I may add,
25 the whole framework here is to think about this in

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 terms of manmade radiation exposure. I would
2 challenge anybody to think about the Earth as a
3 radiation source. And think about the increment that
4 is manmade.

5 So the whole background question comes in
6 in such a way that as you've pointed out, the
7 framework, in my view, collapses. So just the basic
8 question of the radiation environment as a global
9 system and the manmade increment on top of that is
10 another reason it collapses.

11 So there's -- and, again, I think there's
12 lots of reasons in my own personal view why that's so.
13 But we'll see how it unfolds.

14 And, again, it leads me to concur -- not
15 that they really -- that I need to or not -- but I
16 mean I believe that the deep misgivings that the
17 Commission has is well founded at this point without
18 significant work to the contrary.

19 Anything else, George?

20 (No response.)

21 VICE CHAIRMAN RYAN: Dr. Garrick?

22 CHAIRMAN GARRICK: Just continuing that
23 thought a little bit, one of the comments I've heard
24 made is if we go in the direction of a standard for
25 the protection of nonhuman species, somewhere along

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 the way we have to establish something as a baseline.
2 You have to start with something.

3 DR. COOL: Correct.

4 CHAIRMAN GARRICK: Was there any work that
5 you are aware of that lead to this proposal that puts
6 any illumination on what that baseline might be?

7 DR. COOL: In fact, that's exactly one of
8 the things that we're trying to remind, not so much
9 ICRP but IAEA as they've been laying out an action
10 plan is the first thing we have to have is an
11 understanding and a baseline. And we need to spend
12 some time making sure that you've got that before you
13 can even consider this other stuff.

14 CHAIRMAN GARRICK: Right. Right. Because
15 it's like George is saying, you just don't know where
16 to start. You have to have some sort of a surrogate
17 or some sort of a starting point, whether it's the
18 lady bug or the pine trees that somehow can be a
19 representative for the environment or representatives.

20 DR. COOL: Right, right. And so in the
21 parallel processing that's going on right now, you've
22 got ICRP and this task group of this main Commission
23 that is attempting to define a set of reference
24 organisms --

25 CHAIRMAN GARRICK: Right.

1 DR. COOL: -- with their, you know,
2 spheroids or whatever, so you can do some calculations
3 of their exposure.

4 And, in parallel, you have other
5 organizations trying to look at the current state of
6 radiation and the effects in the environment through
7 UNSCARE and others.

8 And you have also going on several efforts
9 to try and do some modeling, RESRAD biota, some other
10 codes over in Europe. And the thought is that these
11 will gradually come together to improve our
12 understanding of our baseline of what we have.

13 Now you might see a couple very large
14 capital ifs in between my lines there, so --

15 CHAIRMAN GARRICK: Yes, yes, okay.

16 DR. COOL: -- as a personal speculation.

17 CHAIRMAN GARRICK: Let me ask you. Do you
18 have any indication of what the international reaction
19 is to the idea of a separate standard for nonhuman
20 species?

21 DR. COOL: It's a bit mixed. You have
22 some countries -- and I would like to be careful in
23 trying to characterize them -- but particularly
24 northern Europe, Scandinavia, who are particularly
25 concerned about protection of the environment who are

1 pushing more strongly for this to move forward.

2 You have other countries that, like us,
3 are very skeptical about the whole process.

4 Much of this could be attributed, in part,
5 to the fact that you have -- particularly in the
6 European Union now, some directive requirements coming
7 in requiring demonstrations of impacts and effects.
8 And people are going oh, this is a very nice
9 directive, European Union. Now exactly how am I
10 supposed to prove to you that I'm not impacting the
11 environment per this directive?

12 So some of this, in fact, you can actually
13 trace back not through the scientific so much but
14 through the legal concern of being able to provide a
15 proper defense in the face of these directives.

16 VICE CHAIRMAN RYAN: Okay. Thank you.

17 John?

18 MR. CLARKE: I just wanted to join the
19 others and say that I, too, will be very interested to
20 see where the ecological piece goes.

21 (Laughter.)

22 MR. CLARKE: If you haven't already, I
23 think you would find it very interesting to go back
24 and look at the non-rad side and how ecological risk
25 assessment has been evolving for stabilized organics

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 and toxic chemicals. And, you know, just try and get
2 your arms around it.

3 As George and John said, where do you
4 start? What are your implants? Which species are you
5 interested in?

6 But I would think all of this could have
7 a big impact on the environmental restoration
8 activities that are going on now where these kinds of
9 non-rad ecological risk assessments are already being
10 done as well.

11 DR. COOL: Yes, I think we would very much
12 agree. We have attempted to comment a couple times
13 that surely we just haven't suddenly gotten smart and
14 we can go off and create something all on our own on
15 the rad side because there has been a lot of work on
16 the other side.

17 It's not entirely clear how much
18 connection there is between the great deal of work
19 that's been done in other forms and how much
20 connection there is. I would hope that that happens.

21 MR. CLARKE: Yes, I think what would be
22 interesting though is how they have struggled with the
23 ultimate goal as well in trying to answer some very
24 fundamental questions.

25 VICE CHAIRMAN RYAN: Don, I've got a few

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 questions on the things that we are going to turn our
2 attention to, hopefully --

3 DR. COOL: Good.

4 VICE CHAIRMAN RYAN: -- in responding to
5 the ICRP's recommendations rather than what we're not
6 really going to respond to.

7 It seems to me that there is kinds of a
8 couple of categories of things. The one category of
9 things is kind of updating the science of calculating
10 dose, particularly internal dose.

11 And it's interesting, and I just kind of
12 summarize that from the 10 CFR 20 that we have and
13 what backs it up to where we are with these new
14 recommendations, there's kind of a -- for any
15 particular isotope or element, there's several steps
16 of modeling that are not up to date.

17 It seems reasonable to think about bring
18 those to some concurrent point rather than having a
19 case-by-case exemption for licensees would be a
20 smoother regulatory system. So there's probably a
21 bunch of tools, if I can call them that, that
22 licensees want to use that are updated, that for
23 whatever reason, they recognize as better science,
24 that would -- it would probably be a very positive
25 thing on how to bring that forward. That's Box 1.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 The second box is how do the fundamental
2 pieces of risk-related factors, whether they're the
3 radiation risk factors or the weighting factors for
4 tissues and so forth, correct me if I'm wrong but I'm
5 just trying to help the Committee understand, all of
6 that has come out of what you mentioned earlier, the
7 Hiroshima/Nagasaki studies and BEIR Reports and so
8 forth from the time frame of '91 when we updated up
9 through the current time. Is that a pretty good
10 general statement?

11 DR. COOL: That's a pretty good general
12 statement. Recognize that the underlying science that
13 Part 20 is based on goes back to '77 and '80.

14 VICE CHAIRMAN RYAN: Yes.

15 DR. COOL: There was, in fact, a step jump
16 in the scientific modeling and things with ICRP 60,
17 which we didn't adopt because of the procedural place
18 that we were in at that time. That is undergoing
19 another revision at this point.

20 Certainly what we are looking at is the
21 hows and whats and implications of leapfrogging
22 directly to more update science --

23 VICE CHAIRMAN RYAN: Right.

24 DR. COOL: -- the risk factors that would
25 go along with that, and a whole set of organizational

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 issues that sooner or later we'll have to deal with
2 because as long as we have all of these codified in
3 the regulations, we have ourselves rather nicely tied
4 together.

5 VICE CHAIRMAN RYAN: Right. A couple
6 other aspects that struck me from your presentation is
7 that -- and I wanted to highlight it for everybody's
8 memory, that the five rem per year limit for a worker
9 under 10 CFR 20 is different from the two rem per year
10 that ICRP recommends.

11 And they have kind of a five-year window
12 and, you know, there might even have been some age-
13 dependency questions earlier on that have tended to
14 not be there now. So I think that sticks out as a
15 difference.

16 Now I put difference in quotes in my own
17 mind because I'm not too sure what the differences in
18 those two numbers means in terms of ultimate risk to
19 the individual. So that's something to think about.

20 I recall that at the time that came around
21 in '91, the idea was that it is rare to see exposures
22 in workers above two in the U.S. And that with the
23 ALARM principle and the current standard, it was felt
24 that we were meeting the obligations for radiation
25 protection that was, in fact, not far out of step with

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 international recommendations.

2 Is that also a --

3 DR. COOL: And that is true. And yet more
4 so true as the years have progressed.

5 VICE CHAIRMAN RYAN: Right.

6 DR. COOL: I can't quote you exact
7 numbers. But there are maybe a couple of hundred
8 folks out of the entire worker population that is
9 required to report to NRC that are over two rem --

10 VICE CHAIRMAN RYAN: Right, so --

11 DR. COOL: -- in any year, so --

12 VICE CHAIRMAN RYAN: -- again, I think
13 that will be a focal point, perhaps, as the staff
14 moves forward in considering this -- I'm sorry --

15 CHAIRMAN GARRICK: No, go ahead.

16 VICE CHAIRMAN RYAN: -- there's a number
17 of these technical points kind of on the worker
18 exposure side more than any other. And the techniques
19 or the calculation method side that might be the bulk
20 of the considerations that you and the ISCORS
21 Committee and other staff here are going to take up.

22 Is that a fair summary?

23 DR. COOL: That's correct.

24 VICE CHAIRMAN RYAN: Okay.

25 DR. COOL: In fact, when you look at these

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 draft recommendations versus where we are in Part 20,
2 there are differences, as you've highlighted. When
3 you look at it vis-a-vis the previous set of ICRP
4 recommendations, Publication 60, there are small
5 evolutions --

6 VICE CHAIRMAN RYAN: Right.

7 DR. COOL: -- almost entirely in the
8 scientific underpinnings. The concepts have matured
9 a bit. They are expressed slightly differently. But
10 it is, as Roger Clarke has billed it, evolutionary,
11 not revolutionary.

12 VICE CHAIRMAN RYAN: I think, too, there's
13 one part of 10 CFR, 10 CFR 61, that actually goes back
14 to ICRP 2 because it's the only one with an organ dose
15 limit.

16 DR. COOL: Don't get me started.

17 (Laughter.)

18 VICE CHAIRMAN RYAN: But that's an
19 artifact for another day.

20 DR. COOL: Right because that's not the
21 only place.

22 VICE CHAIRMAN RYAN: Mr. Chairman?

23 CHAIRMAN GARRICK: You may have answered
24 this but where does the NCRP stand on all of this?

25 DR. COOL: I'm sure NCRP will be putting

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 in some comments. NCRP's last publication more or
2 less mirrored ICRPs'60, although I'm not recalling
3 because I haven't looked lately what they did on the
4 occupational piece nor have I talked with Tom Tenforde
5 lately to know whether they may go through some sort
6 of update on their recommendations down the line a
7 bit.

8 I just haven't had a chance to talk to him
9 on what NCRP's plans may be at this point.

10 CHAIRMAN GARRICK: Oh, thank you.

11 VICE CHAIRMAN RYAN: Thanks. Any other
12 questions or comments?

13 I think in closing, Don, we're looking
14 forward to, perhaps, a working group meeting with you
15 and others to help in any way we can to, you know,
16 provide input for comments or to facilitate
17 information gathering. And I think we would envision
18 a letter to the Commissioners that would come out of
19 that process in support of your investigations.

20 I think we've talked about working with
21 you on schedule in a way that helps you meet your
22 obligations to get material to the Commission and then
23 subsequently out the door on schedule.

24 So we'll continue, if it is okay with the
25 Chairman, the Committee -- I'll work with you to see

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 if we can make that happen.

2 CHAIRMAN GARRICK: Excellent.

3 DR. COOL: Very good. We appreciate that.

4 VICE CHAIRMAN RYAN: Thank you very much
5 for your time and very informative presentation today.

6 DR. COOL: Thank you.

7 CHAIRMAN GARRICK: Thank you.

8 (Whereupon, the above-entitled meeting was
9 concluded at 2:27 p.m.)

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

CERTIFICATE


This is to certify that the attached proceedings
before the United States Nuclear Regulatory Commission
in the matter of:

Name of Proceeding: Advisory Committee on
Nuclear Waste
152nd Meeting

Docket Number: n/a

Location: Rockville, MD

were held as herein appears, and that this is the
original transcript thereof for the file of the United
States Nuclear Regulatory Commission taken by me and,
thereafter reduced to typewriting by me or under the
direction of the court reporting company, and that the
transcript is a true and accurate record of the
foregoing proceedings.



Emily Winters
Official Reporter
Neal R. Gross & Co., Inc.

NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701



Overview of Draft ICRP Recommendations

JULY 21, 2004

1



Background

- NRC Revised 10 CFR Part 20 published in 1991 based on ICRP 26 and 30
- ICRP Revised Recommendations, Report 60, published in 1991
- Exemptions currently granted for use of ICRP Publication 60 and following methodologies on a case by case basis

2



Background

- NRC staff alternatives for considering revisions contained in SECY-01-0148
- Alternatives included no action, beginning rulemaking, and waiting for revised ICRP recommendations to be completed
- Commission direction to work with other Federal Agencies to ensure a coherent approach and to monitor the work of ICRP

3



Background

- SECY-04-0030 provided staff recommendations for a more robust materials research program, including a proposal to be more proactive in radiation protection activities
- SECY-04-0055 provided staff recommendations and plan for evaluating scientific information and radiation protection recommendations
- SRM's dated April 12 and May 13, 2004 approved staff plans with the exception of research activities on protection of the environment.

4



NRC Participation

- NRC staff has commented directly to ICRP and participated in NEA/CRPPH Expert Group Activities
- NRC staff has contributed discussions in International Forums, National Meetings, and other venues



ICRP Public Consultation

- ICRP recommendations draft published June, 2004
- Comments to be transmitted to ICRP by end of year




RP05 Features

- Recommending dose constraints that quantify the most fundamental levels of protection for workers and the public from single sources in all situations.
- Maintaining the Publication 60 limits for the combined dose from all regulated sources that represent the most that will be accepted in normal situations by regulatory authorities



RP05 Features Levels of Concern





RP05 Features Maximum Constraints for a Single Source

100 mSv	Emergency situations
20 mSv	Occupational Exposure
1 mSv	Public Exposure
0.01 mSv	Minimum Constraint



RP05 Features

- Complementing the constraints and limits with the requirement for optimization of protection from a source
- Recognizing where the responsibility for justifying the introduction of a new practice lie

10



RP05 Features

- Updating the radiation and tissue weighting factors in Effective Dose
- Fatal cancer risk coefficient increases, but total detriment risk coefficient decreases
- Emphasizing that patient dose should be commensurate with the clinical benefit expected from a given justified diagnostic or therapeutic procedure
- Including a policy for radiological protection of non-human species

11



Protection of Environment

- Chapter in ICRP general recommendations draft
- ICRP Committee 5 (new)
- Task Group currently working on reference animals and plants

12



Protection of Environment

- Objectives of a common approach:
 - "Safeguard human health by preventing the occurrence of deterministic effects; limiting stochastic effects in individuals and optimizing the protection of populations; and to
 - safeguard the environment by reducing the frequency of effects likely to cause early mortality, or reduced reproductive success, in animals and plants to a level where they would have a negligible impact on conservation of species, maintenance of biodiversity, or the health and status of natural habitats or communities."

13



Protection of Environment

- "The Commission continues to have deep misgivings about the need to go forward with the development of a separate standard for protection of non-human species.."
- Any framework and process should allow national flexibility and be performance-based

14



Visit by ICRP

- Plans are being made for the ICRP Chairman and Vice-Chairman to visit NRC in September, 2004.
- ICRP representatives have offered to meet with NRC staff, other Federal agency representatives, and members of the public

15



U.S. Review Process

- Agency and U.S. interagency reviews underway
- U.S. Interagency coordination through ISCORS Federal Guidance Subcommittee
- Input comments to NEA CRPPH Expert Group

16

INTEGRATED SAFETY ANALYSIS

(INFORMATION BRIEFING)

**Sharon Steele
ACRS/ACNW
July 21, 2004**


Objectives

- I. Provide background on 10 CFR Part 70, Subpart H requirements - Integrated Safety Analysis (ISA)
- II. Provide example of ISA summary submittal
- III. Recent Developments

I. Risk-Informed Regulation and Guidance

- **New Rule (Subpart H of 10 CFR Part 70) issued in 2000**
- **New Staff Guidance:**
 - ◆ NUREG-1520, "Standard Review Plan for the Review of a License Application for a Fuel Cycle Facility", March 2002
 - ◆ NUREG-1513, "Integrated Safety Analysis Guidance Document", May 2001
 - ◆ Applicable Guidance: NUREG/CR-6410, "Nuclear Fuel Cycle Facility Accident Analysis Handbook", March 1998
- **By October 2004, licensees are required to:**
 - ◆ Complete a site-wide ISA
 - ◆ Correct all unacceptable performance deficiencies
 - ◆ Submit a site-wide ISA Summary for NRC approval
- **Applies to nuclear fuel fabrication facilities and new enrichment facilities**


10 CFR Part 70 Regulatory Concept



Focus - Integrated Safety Analysis:

- Use Systematic Methods to:
 - (1) Identify Accidents,
 - (2) Determine Likelihoods, and
 - (3) Estimate Consequences
- Integrate Radiological, Criticality, Fire, Chemical and Environmental Safety Disciplines
- Comply with performance requirements
- Identify Items Relied on for Safety (IROFS), and establish management measures for the IROFS

Parameters of Performance Requirements



- Must demonstrate that accident sequence is *highly unlikely*, if:

- * Worker receives

- (1) 100 rem or more
- (2) life-endangering chemical exposure



- * Public (Outside “Controlled Area”) receives:

- (1) 25 rem or more
- (2) Greater than 30 mg soluble uranium intake
- (3) Irreversible chemical injury

Parameters of Performance Requirements

-continued-

- Must demonstrate that accident sequence is *unlikely*, if:
 - * Worker receives
 - (1) More than 25 rem but less than 100 rem
 - (2) Irreversible chemical injury

 - * Public (Outside “Controlled Area”) receives
 - (1) Greater than 5 rem but less than 25 rem
 - (2) Chemically-induced transient illnesses

 - * Environment (outside ‘restricted area’)
 - (1) Concentration > 5000 times yearly average releases (10 CFR 20 App B Table 2 value)

10 CFR 70.61 Performance Requirements -continued-

	Highly Unlikely	Unlikely	Not unlikely
High Consequence Publ Dose > 25 rem Worker Dose > 100 rem	Acceptable	Not Acceptable	Not Acceptable
Medium Consequence Publ Dose 5 - 25 rem Worker Dose 25 -100 rem Env releases > 5000 Tbl 2	Acceptable	Acceptable	Not Acceptable
Low Consequence Publ Dose < 5 rem Worker Dose < 25 rem	Acceptable	Acceptable	Acceptable

Likelihood Qualities

■ Qualitative


- ◆ Large safety margin
- ◆ Low failure rate
- ◆ Preference of controls (passive, active, administrative)
- ◆ High level of QA
- ◆ Surveillance capability
- ◆ Redundancy
- ◆ Protection from common cause failures

■ Quantitative

- ◆ NUREG-1520 (Standard Review Plan) provides quantitative guidelines for high- and intermediate-consequence accident sequences
- ◆ These are based on less than 1 major fuel cycle event in 100 years


ISA-Related Licensing Outcomes

- Streamlined license will
 - ◆ Potentially reduce the number of amendments
 - ◆ Shorten license renewal time
 - ◆ Improve efficiency and effectiveness
 - ◆ Reduce regulatory burden
- Licensees can make facility and procedure changes without prior NRC approval, if the change does not:
 - ◆ Downgrade an IROFS
 - ◆ Create a new type of severe accident
 - ◆ Alter a sole IROFS
- Licensees must submit annually a summary of all such changes to the NRC
- Annual ISA Summary updates could significantly reduce the need for and scope of renewals



II. Example - NFS Blended Low Enriched Uranium (BLEU) Project

Off-Spec HEU Materials




- Three license amendment applications the BLEU project:
 - (1) Uranyl Nitrate Building (UNB),
 - (2) BLEU Preparation Facility,
 - (3) Oxide Conversion /Effluent Processing Buildings
- On February 2002 – NFS requested authorization to receive and store low-enriched Uranyl nitrate solutions in a new storage building – UNB.
- New process, new building => ISA

Overall NFS BLEU ISA Process

STEPS:

- Convene a team of qualified safety professionals (PHA)
- Perform individual and specific hazards analyses to identify hazards and accident sequences (HAZOPS)
- Assess and bin consequences of concern, i.e. "high" or "intermediate"
- Categorize likelihood of each accident sequence (used Risk-Index method)
- Identify IROFS to control each accident which results in consequences of concern



Consequence Severity Categories

- Assess and bin consequences of concern, i.e. "high" or "intermediate"

	Limit for Workers	Limit for Offsite Public	Limit for Environment
Consequence Category 3 (High Consequence)	1) TEDE \geq 100 rem 2) Chemical Release \geq ERPG3	1) TEDE \geq 25 rem 2) Chemical Release \geq EPRG2 3) \geq 30mg sol. Uranium Intake	See Intermediate Consequence Category 2
Consequence Category 2 (Intermediate Consequence)	1) TEDE is \geq 25 rem and $<$ 100 rem 2) Chemical Release \geq EPRG2 and $<$ EPPG3	1) TEDE is \geq 5 rem and $<$ 25 rem 2) Chemical Release \geq EPRG1 and $<$ EPPG2	Radioactive release 24-hour average) 5000 * Table 2 Appendix B of 10 CFR Part 20
Consequence Category 3 (Low Consequence)	Accidents with lower consequences than Cat. 2 above	Accidents with lower consequences than Cat. 2 above	Releases with lower conseq. than Cat 2 above

Example: NFS BLEU Uranyl Nitrate Building

Initiating Event Frequency – Index Assignments

Table 3: Initiating Event Frequency

Frequency Index	Failure Frequency	Description	Comments
-5	1 Failure/100,000 years	Not credible	If initiating event, no IROFS needed
-4	1 Failure/10,000 years	Physically possible, but not expected to occur.	
-3	1 Failure/1,000 years	Not expected to occur during plant lifetime.	
-2	1 Failure/100 years (Loss of cooling (redundant cooling water pumps)) (Loss of Power (redundant power supplies))	Not expected, but might occur during plant lifetime.	
-1	1 Failure/10 years	Expected to occur during plant lifetime.	
0	1 Failure/year (Loss of cooling) (Loss of Power)	Expected to occur regularly during plant lifetime.	
1	Several occurrences per year	A frequent event	

- Categorize likelihood of each accident sequence
- (NFS used Risk-Index method)

- An Initiating Event Frequency Index is assigned to each credible accident scenario
- Based on past experience, engineering judgment, analytical data, industry acceptable values, and/or any other applicable information.

Example: NFS BLEU Uranyl Nitrate Building

IROFS Failure Index

Table 4: IROFS Failure Index

- Categorize likelihood of each accident sequence
- Identify IROFS to control each accident sequence
- Assign Failure index

Effectiveness of Protection Index	Type of IROFS**
-4 ^a ***	Protected by an exceptionally robust inspected passive engineered control (PEC), Exceptionally Robust Management Measures to ensure availability.
-3 ^a	Protected by an inspected single PEC or exceptionally robust functionally tested AEC with a trained operator backup. Adequate Management Measures to ensure availability.
-2 ^a	Protected by a single functionally tested AEC. Protected by a trained operator performing a routine task with an approved procedure, an enhanced administrative control, or an administrative control with large margin. Adequate Management Measures to ensure availability.
-1	Protected by a single administrative control or a trained operator performing a non-routine task with an approved procedure.
0	No protection

Example: NFS BLEU Uranyl Nitrate Building

Total Risk Likelihood Category

- Categorize likelihood of each accident sequence

Table 6: Total Risk Likelihood Category

Likelihood Category	Likelihood Index T (=sum of index numbers)
1	$T \leq 4$
2	$4 < T \leq 3$
3	$T > 3$

- **Likelihood Index, T = Initiating Event Failure Frequency + IROFS Failure Index** (two previous slides)
- Can demonstrate the relative importance of the IROFS in preventing or mitigating the accident sequence

Example: NFS BLEU Uranyl Nitrate Building

Risk Matrix

- Determine acceptability of severity-likelihood pair

Severity of Consequences	Likelihood of Occurrence		
	Likelihood Category 1 Highly Unlikely (1)	Likelihood Category 2 Unlikely (2)	Likelihood Category 3 Not Unlikely (3)
Consequence Category 3 High (3)	Acceptable Risk 3	Unacceptable Risk 6	Unacceptable Risk 9
Consequence Category 2 Intermediate (2)	Acceptable Risk 2	Acceptable Risk 4	Unacceptable Risk 6
Consequence Category 1 Low (1)	Acceptable Risk 1	Acceptable Risk 2	Acceptable Risk 3

Example: NFS BLEU Uranyl Nitrate Building

Selected Accident Sequence Summaries which Require IROFS and Resultant Risk Assignments

(1) Accident Sequence	(2) Initiating Event <hr/> Freq Index	(3) Preventive IROFS 1 <hr/> Freq Index	(4) Preventive IROFS 2 <hr/> Freq Index	(5) Mitigation <hr/> Freq Index	(6) Likelihood Index T Uncontrolled <hr/> Controlled	(7) Likelihood Category Uncontrolled <hr/> Controlled	(8) Consequence <hr/> Category	(9) Risk Indices Uncontrolled <hr/> Controlled	(10) Comments and Recommendations
1.5.1 High U conc. of %235	Shipper emp, erroneous U/N received into TK-10			None	U = -3	U = 2	Possible Criticality Accident	U = 6	<i>High quality vendor process and safety controls make initiating event unlikely.</i>
	-3	-1	-2		C = -6	C = 1	3	C = 3	
1.5.2 UN Receipt High U in TK-10	UN Freezing in Shipping Container			None	U = 0	U = 3	Possible Criticality Accident	U = 0	<i>This scenario can only occur during transfers (one per week) that take place in extremely cold weather.</i>
	0	-2	-2		C = -4	C = 1	3	C = 3	
1.7.1 UN Receipt High U in TK-10	UN Freezing in Shipping Container			None	U = 0	U = 3	Possible Criticality Accident	U = 0	<i>Essentially the same as 1.5.2</i>
	0	-2	-2		C = -4	C = 1	3	C = 3	

Example: NFS BLEU Uranyl Nitrate Building

Selected Accident Sequence Summaries -Continued-

(1) Accident Sequence	(2) Initiating Event	(3) Preventive IROFS 1	(4) Preventive IROFS 2	(5) Mitigation	(6) Likelihood Index T		(7) Likelihood Category	(8) Consequences	(9) Risk Indexes	(10) Comments and Recommendations
	Freq Index	Freq Index	Freq Index	Freq Index	Uncontrolled	Controlled	Uncontrolled	Controlled	Uncontrolled	
1.12.1 UN Receipt: High U in TK-10	Precipitant transferred to TK-10 from a LR-100			None	U = -1	U = 3	Possible Criticality Accident	U = 9	LR-230 are unique to this service. No precipitating agents are allowed in suppliers downloading areas or upstream equipment.	
	-3	-1	-2		C = -6	C = 1	3	C = 3		
1.12.2 UN Receipt: High U in TK-10	Operator Transfers Precipitant via Feed Line			None	U = -1	U = 3	Possible Criticality Accident	U = 9	No precipitants (or other chemicals other than UN) are used in the UNB download area.	
	-1	-3	-1		C = -6	C = 1	3	C = 3		
1.18.1 UN Receipt High U in TK-10 (Feed Line)	UN Freezing in Shipping Container			None	U = 0	U = 3	Possible Criticality Accident	U = 9	Essentially the same as 1.6.2	
	0	-2	-2		C = -4	C = 1	3	C = 3		
1.25.1 UN Dedstock from TK- 10	High Flow in Off-Spec Material Feed Line causes U converter, w/ subsequent evaporation			None	U = -1	U = 3	Possible Criticality Accident	U = 9	Level controls/interlocks and CCS control of transfers to TK-10 provide added protection against any overfill scenario.	
	-1	-3	-3		C = -7	C = 1	3	C = 3		

Example: NFS BLEU Uranyl Nitrate Building

Selected Natural Phenomena, Fire and External Event Scenarios

Scenario #	Initiating Events	Unmitigated Consequence	Controls/Mitigating Factors
1	Earthquake	Potential to rupture multiple tanks in the UNB, causing radiological contamination extending outside of the building.	<p>UNB and UN storage tank restraint system are designed to meet or exceed 1999 SBC Zone IIC seismic requirements (0.1g horizontal acceleration).</p> <p>NFS seismic analysis determined that for a 1,000 year return period, the horizontal acceleration is 0.06 g.</p> <p>Small falling objects (i. e. pipe, light fixtures, pieces of metal siding, etc.) will not cause catastrophic failure of tanks. The probability of earthquake damage severe enough to cause failure of major structural components of the building and subsequent catastrophic damage to multiple tanks is Low.</p> <p>An evaluation of damage after a 1994 earthquake in California with horizontal acceleration of 0.5 g showed properly anchored FRP tanks were undamaged. The probability of earthquake damage severe enough to cause failure of multiple tanks in a manner that would allow the total contents to spill is Low.</p> <p>No criticality issues due to concentration control. No short-term mechanism to concentrate solution.</p>
2	Storm - High Winds	Potential for building damage and subsequent rupture of multiple tanks in the UNB, causing radiological contamination extending outside of the building.	<p>UNB is designed to withstand 80 mph wind in accordance with the Standard Building Code.</p> <p>NOAA data collected at the regional airport indicates maximum sustained wind of 50 mph (recorded in 1951) and a peak gust of 86 mph (recorded in 1995).</p> <p>Small objects striking tanks at or near the top will not cause damage that would allow the total contents of the tank to spill. The probability of wind damage severe enough to cause failure of major structural components of the building and subsequent catastrophic damage to multiple tanks is Low.</p> <p>No criticality issues due to concentration control. No short-term mechanism to concentrate solution.</p>

Example: NFS BLEU Uranyl Nitrate Building

Natural Phenomena, Fire and External Event Scenarios -continued-

Scenario #	Initiating Events	Unmitigated Consequence	Controls/Mitigating Factors
3	Tomado	Potential for building damage and subsequent rupture of multiple tanks in the UNB, causing radiological contamination extending outside of the building.	<p>UNB is designed in accordance with the Southern Building Code.</p> <p>One tomado recorded in county since 1950.</p> <p>Tomadoes travel in narrow irregular paths tending to strike higher terrain rather than valleys. Likelihood of a tomado striking UNB is Low.</p> <p>Small falling objects striking tanks at or near the top will not cause damage that would allow the total contents of the tank to spill. The probability of tomado damage severe enough to cause failure of major structural components of the building and subsequent catastrophic damage to multiple tanks is Low.</p> <p>No criticality issues due to concentration control. No short-term mechanism to concentrate solution.</p>
4	Hurricane	Potential for building damage and subsequent rupture of multiple tanks in the UNB, causing radiological contamination extending outside of the building.	<p>Plant location is too far inland to be considered a credible risk due to hurricane.</p> <p>No criticality issues due to concentration control. No short-term mechanism to concentrate solution.</p>
5	Flood	Potential to rupture multiple UN storage tanks causing radiological contamination extending outside of the building.	<p>Plant location is above the 100 year flood level of all nearby rivers and streams (100 year flood plain of Martin Creek is 1640 feet, floor of UNB is 1655 feet).</p> <p>No criticality issues due to concentration control. No short-term mechanism to concentrate solution.</p>
6	Site evacuation with operators leaving stations prior to shut down	Deviations from designed process that could occur due to operator error or absence and which may result in an accident scenario with significant consequence.	HAZOPS analysis (summary table in Section 13.0) verifies that the process design includes passive and/or engineered fail-safe controls to protect against potentially hazardous deviations in case of operator absence.

Example: NFS BLEU Uranyl Nitrate Building

Management Measures for Items Relied on For Safety (IROFS)

- NFS specified IROFS:
 - ◆ Passive Engineered (**most preferred**)
 - ◆ Active Engineered
 - ◆ Enhanced Administrative, and
 - ◆ Administrative (**least preferred**)
 - NFS specified management controls – available, reliable.
 - ◆ Applied to design, construction, operations, maintenance and change control of IROFS
 - ◆ May be graded commensurate with the level of risk reduction
- 

Example: NFS BLEU Uranyl Nitrate Building

Evaluation Findings

- ◆ “Specifically, the NRC staff finds that the ISA results, as documented in its ISA Summary, provide reasonable assurance that the IROFS, management measures, and NFS’ programmatic commitments will, if properly implemented, make all credible intermediate consequence accidents unlikely and all credible high consequence accidents highly unlikely.”
- ◆ “The NRC staff finds these commitments [management measures to maintain the reliability of IROFS] acceptable.”

III. Recent Developments

- Licensee ISA status
- Interim Staff Guidance (DRAFT)
- July 2004 Workshop - outcomes

Status of ISA Summaries:

- Received from licensee and approved by NRC:
 - ◆ NFS BLEU Project - Uranyl Nitrate Building
 - ◆ NFS BLEU Project - BLEU Preparation Facility
 - ◆ USEC - Pilot Plant

- Received from licensee and under review by NRC:
 - ◆ NFS BLEU Project - Oxide Conversion and Effluent Processing
 - ◆ Global Nuclear Fuels - Americas (GNF-A) - Dry Conversion and HF Recovery
 - ◆ Westinghouse (WEC) - Wastewater Treatment and UN Storage
 - ◆ LES - Application and Site-Wide ISA Summary

- Not yet received from licensee but due before Oct 18, 2004:
 - ◆ GNF-A - Balance of Plant
 - ◆ WEC - Balance of Plant
 - ◆ Framatome-Richland - Site-Wide
 - ◆ Framatome-Lynchburg - Site-Wide

- USEC and MOX may come in with their ISA Summaries this fall

Interim Staff Guidance Documents Under Development

- ISG-01, Methods for Qualitative Evaluation of Likelihood
- ISG-02, Accident Sequences/Radiation Risk
- ISG-03, Nuclear Criticality Safety Performance Requirements
- ISG-04, Clarification of Baseline Design Criteria
- ISG-05, Additional Reporting Requirements
- ISG-06, Alternative Schedules and Compensatory Measures
- ISG-07, Rules of Engagement
- ISG-08, Addressing Natural Phenomena in ISAs (Future)
- ISG-09, Initiating Event Frequency (Future)

July 2004 Workshop / Discussion Topics

- Backfit Guidance
- Addressing Natural Phenomena
- Nuclear Criticality Safety
- Initiating Event Frequency
- Methods for Qualitative Evaluation of Likelihood
- Management Measures
- Items Relied on for Safety, Challenges to IROFS
- Baseline Design Criteria
- Rules of Engagement
- Accident Sequences Resulting in Low Dose Consequences
- 10 CFR 70.72 Facility Changes and Change Process
- Alternative schedule - Deficiencies and Implementation of Compensatory Measures
- Inspection Planning